Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial Top-line Data On Track to be Reported During Q3 2018 Oxford, UK, and Cambridge, MA, US, 19 April 2018 - Summit Therapeutics plc ...

PhaseOut DMD is a 48-week open-label trial that has enrolled 40 patients at sites in the UK and the US. As part of the trial, each patient undergoes two biopsies, a baseline biopsy on enrolment ...

--MicroCloud Hologram Inc.,, a technology service provider, they proposed a two-qubit dephasing noise spectral protocol based on continuous control modulation, specifically adopting effective ...

DMD affects an estimated one in every 3,500–5,000 male births, with an estimated 12,000–15,000 patients in the United States and approximately 25,000 patients in Europe.